logo-loader
RNS
Allergy Therapeutics PLC

Allergy Therapeutics - Grant of Awards under Long Term Incentive Plan

RNS Number : 1161G
Allergy Therapeutics PLC
02 November 2018
 

 

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Grant of Awards under Long Term Incentive Plan

 

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTIP") the following conditional awards of shares of 0.1 pence each were made to Executive Directors at a nominal cost of 0.1 pence each on 1 November 2018 (the "Awards").

 

 

Executive Director

Number of Conditional shares awarded

Total conditional shares held under LTIPs

Manuel Llobet

900,000

3,490,000

Nick Wykeman

450,000

1,322,500

 

 

The Awards have been granted in accordance with the LTIP rules and vesting is conditional on the satisfaction of performance conditions in respect of earnings growth and share price growth.  

 

In addition, Manuel Llobet holds share options in respect of 2,155,423 shares relating to a vested LTIP award.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Manuel Llobet

Nicolas Wykeman

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Manuel Llobet - Chief Executive Office and PDMR

Nicolas Wykeman - Chief Financial Officer and PDMR

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

ALLERGY THERAPEUTICS PLC

b)

 

LEI

 

 

213800PQ7AHK7KGVOE23

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

 

 

 

Conditional award of shares under the Company's Long Term Incentive Plan

 

 

 

 

 

b)

Identification code

GB00B02LCQ05

c)

 

Nature of the transaction

 

 

Grant of Conditional Awards

d)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.001

900,000

£0.001

450,000



 

 

e)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

 

 N/A (Single transaction)

 

 

 

f)

 

Date of the transaction

 

 

1 November 2018

g)

 

Place of the transaction

 

 

Outside a trading venue

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon  

+44 (0) 20 7886 2500

Freddy Crossley / Emma Earl, Corporate Finance

Erik Anderson, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Nick Brown

allergytherapeutics@consilium-comms.com

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDDBDBGBGBGIB
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read